MiCAN Technologies, Inc. (Headquarters: Kyoto, Japan; President: Kazuo Miyazaki) has established a subsidiary in Heidelberg, Germany. MiCAN Technologires EUROPA GmbH has started to offer a new thermogenic test product (MylcMAT®) for the European market, using immortalized monocyte cells (aMylc), which is a regenerative medicine technology.
Background of the Subsidiary Establishment in Germany
MiCAN Technologies has successfully developed immortalized monocyte cells (aMylc cells) specifically for pyrogen testing, utilizing its proprietary technology for creating immortalized hematopoietic cells. We have also developed a pyrogen test, MylcMAT®, based on these aMylc cells.
Currently, due to concerns for animal welfare and the quality control of new modality products such as regenerative medicine, monocyte activation tests (MAT) using human monocytic cell lines are attracting attention as an alternative to the conventional rabbit pyrogen test. This trend is particularly prominent in Europe, a leading region in animal welfare. To further expand our global presence, including in Europe, we have decided to establish a subsidiary in Germany.
